Outcome of Board Meeting
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.5 pts less than Nifty Microcap 250 and 11.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hikal Ltd reported FY2026 standalone revenue of Rs 17,126 million, down 8% from Rs 18,598 million in FY2025, due to USFDA warning letter impact on pharma sales. The company posted a net loss of Rs 487 million versus profit of Rs 909 million in prior year, impacted by Rs 851 million in exceptional items (Rs 471M asset impairment from plant repurposing + Rs 380M labour code adjustments). Q4 saw an impairment charge of Rs 471M for assets no longer usable. The Board recommended final dividend of 20% (Rs 0.40/share) bringing total FY dividend to 30% (Rs 0.60/share including Rs 0.20 interim). Auditors issued unmodified (clean) opinion. Environmental compliance matter remains pending before Hon'ble Supreme Court (NGT compensation claim of Rs 174.5M stayed, Rs 50M deposited). Operating cash flow was healthy at Rs 3,021 million. Mr. Sandip Parikh appointed as Additional Independent Director for 5 years.
FY2026 was severely impacted by USFDA regulatory action on Jigani plant, large exceptional items, and revenue decline. However, clean audit opinion, positive operating cashflow, and dividend continuation indicate operational resilience despite the loss-making year. The environmental case pending in Supreme Court remains a contingent risk.